San Jose, CA, USA and Göttingen, Germany (3 May, 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces that it will present clinical data relating to its cell-free DNA copy number instability (CNI) diagnostic at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting 2016 at McCormick Place in Chicago, Illinois on 3-7 June 2016.


The following abstract will be presented during the poster session:


Title: Tumor cell-free DNA copy number instability (CNI) to predict therapeutic response to immunotherapy prior to cycle 2 (Abstract #3027)


Presenter: Glen J. Weiss, MD, MBA, Cancer Treatment Centers of America®


Location: POSTER SESSION (Developmental Therapeutics – Immunotherapy), Hall A, Poster Board: #349


Date/Time: Sunday, 5 June, 2016 – 8:00 AM – 11:30 AM CDT


The study was conducted by Dr. Glen Weiss and colleagues at Cancer Treatment Centers of America® at Western Regional Medical Center in Goodyear, AZ.


About ASCO Annual Meeting 2016

The American Society of Clinical Oncology (‘ASCO’) Annual Meeting brings together 30,000 oncology professionals from around the world. Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Science sessions present the latest ground-breaking research in oral and poster format.

The theme for ASCO 2016 is Collective Wisdom: The Future of Patient-Centered Care and Research.

About Cancer Treatment Centers of America®

Cancer Treatment Centers of America Global, Inc. (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-based supportive therapies designed to help patients physically and emotionally by enhancing their quality of life while reducing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Consistently rated among U.S. hospitals that deliver the highest quality of care and patient experience, CTCA provides patients and their families with comprehensive information about their treatment options and encourages their active participation in treatment decisions. For more information, visit, and

About Chronix Biomedical

Chronix Biomedical, Inc. is a US-based molecular diagnostics company developing blood tests primarily for the screening and monitoring of cancer. Chronix already offers supplemental screening evaluation tests based on copy number instability for breast and prostate cancer through its own certified laboratories in Göttingen, Germany. The prostate cancer test can discriminate between prostate cancer and other prostate conditions (such as benign prostatic hypertrophy and prostatitis) thereby avoiding invasive needle biopsies when unnecessary. These Chronix supplementary tests assist oncologists in making cancer diagnoses and can reduce costs to healthcare providers by preventing unnecessary procedures such as tissue biopsies. For more information visit